Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 2Phase 1/2 1Phase 1 1

Status

Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 145Breast Neoplasms 113Prostatic Neoplasms 58Multiple Myeloma 57Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 42Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 34Leukemia, Lymphocytic, Chronic, B-Cell 33Colorectal Neoplasms 32Carcinoma, Renal Cell 26Recurrence 25Leukemia, Myeloid, Acute 25Urinary Bladder Neoplasms 23Myasthenia Gravis 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 21Lymphoma, Large B-Cell, Diffuse 21Squamous Cell Carcinoma of Head and Neck 20Small Cell Lung Carcinoma 20Lymphoma, Follicular 18Fallopian Tube Neoplasms 18Endometrial Neoplasms 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 17Melanoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Pancreatic Neoplasms 15Non-Muscle Invasive Bladder Neoplasms 15

Interventions

osimertinib 1HM781-36B 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NSCLC × 90 days × Clear all
NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended
268 enrolled
Thoracic

NSCLC

NCT07376382 2026-05-13

SYNSTAR-02

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
680 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡